{"protocolSection":{"identificationModule":{"nctId":"NCT06085378","orgStudyIdInfo":{"id":"IIT-2023-509"},"organization":{"fullName":"First Affiliated Hospital, Sun Yat-Sen University","class":"OTHER"},"briefTitle":"Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus","officialTitle":"Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus (TK-SEEK): a Prospective, Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study","acronym":"TK-SEEK"},"statusModule":{"statusVerifiedDate":"2023-10","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-01-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-09-07","studyFirstSubmitQcDate":"2023-10-13","studyFirstPostDateStruct":{"date":"2023-10-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-13","lastUpdatePostDateStruct":{"date":"2023-10-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Jinsheng Zeng, MD, PhD","investigatorTitle":"Professor","investigatorAffiliation":"First Affiliated Hospital, Sun Yat-Sen University"},"leadSponsor":{"name":"First Affiliated Hospital, Sun Yat-Sen University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.","detailedDescription":"The study process lasts for a total of 90 days, including the screening period, intervention period, and follow-up period. During the intervention period, the experimental group is treated with Urinary Kallidinogenase, while the control group is treated with placebo for 10 days. Both groups receive routine clinical treatment. All patients are followed up until the 90th day after stroke. The sample size of the study is 630 patients. The ratio of the experimental group to the control group is 1:1."},"conditionsModule":{"conditions":["Acute Ischemic Stroke","Type 2 Diabetes"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":630,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Urinary Kallidinogenase for injection","type":"EXPERIMENTAL","description":"Patients in this arm will be given urinary kallidinogenase for injection, 0.15 peptide nucleic acids(PNA), once a day for 10 days","interventionNames":["Drug: Urinary Kallidinogenase for injection"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"An inactive substance identical in appearance to the urinary kallidinogenase for injection, once a day for 10 days","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"Urinary Kallidinogenase for injection","description":"The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days","armGroupLabels":["Urinary Kallidinogenase for injection"],"otherNames":["KLK、HUK"]},{"type":"OTHER","name":"Placebo","description":"The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days","description":"The proportion of patients with modified rankin scale (mRS) 0-2 scores at 90±7 days","timeFrame":"90±7 days"}],"secondaryOutcomes":[{"measure":"The proportion of patients with modified rankin scale (mRS) 0-3 scores at 90±7 days","description":"The proportion of patients with modified rankin scale (mRS) 0-3 scores at 90±7 days","timeFrame":"90±7 days"},{"measure":"Distribution of modified rankin scale (mRS) at 90±7 days","description":"Distribution of modified rankin scale (mRS) at 90±7 days","timeFrame":"90±7 days"},{"measure":"Changes of NIHSS from baseline to 10 days","description":"Changes of NIHSS from baseline to 10 days","timeFrame":"from baseline to day 10"},{"measure":"Changes of Barthel index from baseline to 90±7 days","description":"Changes of Barthel index from baseline to 90±7 days","timeFrame":"from baseline to day 90±7"},{"measure":"Changes of mini-mental state examination (MMSE) from baseline to 90±7 days","description":"Changes of mini-mental state examination (MMSE) from baseline to 90±7 days","timeFrame":"from baseline to day 90±7"},{"measure":"Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days","description":"Changes of Montreal cognitive assessment (MoCA) from baseline to 90±7 days","timeFrame":"from baseline to day 90±7"}],"otherOutcomes":[{"measure":"Changes of fasting blood glucose values from baseline to 10 days","description":"Changes of fasting blood glucose values from baseline to 10 days","timeFrame":"from baseline to day 10"},{"measure":"Changes of HBA1c from baseline to 90±7 days","description":"Changes of HBA1c from baseline to 90±7 days","timeFrame":"from baseline to day 90±7"},{"measure":"Changes of hypersensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6)","description":"Changes of hypersensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6)","timeFrame":"from baseline to day 10"},{"measure":"Changes of urea nitrogen, creatinine and urinary protein","description":"Changes of urea nitrogen, creatinine and urinary protein","timeFrame":"from baseline to day 10"},{"measure":"Stroke recurrence rate within 90 days","description":"Stroke recurrence rate within 90 days","timeFrame":"90 days"},{"measure":"Incidence, severity, and causality of adverse events (AE) and serious adverse events (SAE) during the intervention","description":"Incidence, severity, and causality of adverse events (AE) and serious adverse events (SAE) during the intervention","timeFrame":"during the intervention"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years old and ≤80 years old;\n* Patients with acute ischemic stroke diagnosed with complete anterior circulation infarction (TACI) and partial anterior circulation infarction (PACI) according to Oxfordshire Community Stroke Project classification (OCSP), see Appendix 6;\n* Refer to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition), have been diagnosed with type 2 diabetes (need to have a medical history to confirm), see Appendix 7;\n* The time from the occurrence of the stroke to the time of admission is less than 48h. If the exact time of onset is unknown, the time of onset of the patient is defined as \"the time that finally seems normal\";\n* First-ever ischemic stroke or have history of ischemic stroke but mRS≤1 before onset;\n* 6≤NIHSS≤20;\n* Have provided signed written informed consent from the patient or the patient's legal representative\n\nExclusion Criteria:\n\n* Acute intracranial hemorrhagic diseases confirmed by imaging: parenchymal hemorrhage, epidural hematoma, subdural hematoma, ventricle hemorrhage, subarachnoid hemorrhage, etc.\n* Patients who are ready to undergo or have undergone intravascular interventional therapy after the onset of the disease;\n* Patients who are ready to undergo or have undergone intravenous thrombolytic therapy after the onset of the disease;\n* Severe disturbance of consciousness: NIHSS 1a consciousness level score ≥2;\n* Patients with fracture, claudication and other factors affecting functional outcome score upon admission;\n* After the onset of the disease, Edaravone injection, Edaravone and Dexborneol concentrated solution for injection, Butylphthalide and sodium chloride injection or Butylphthalide soft capsules have been used;\n* Chinese patent medicine injection for improving cerebral blood circulation has been applied after the onset of this disease (see 8.4.2 for details);\n* Patients with hypotension (blood pressure less than 90/60mmHg) upon admission;\n* Have a history of severe food or drug allergy, or have been allergic to or intolerant of Eurecline injection;\n* Eurecline for injection has used angiotensin-converting enzyme inhibitor (ACEI) drugs before taking the drug and has not exceeded 5 half-lives (according to the specific drug instructions);\n* Patients who are pregnant or breastfeeding and who plan to become pregnant within 90 days;\n* Renal failure or severe renal impairment at the time of screening (creatinine clearance \\< 30ml/min);\n* Liver function impairment: alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\> 2.5 times the upper limit of normal, or other known serious liver diseases such as active infection of acute and chronic hepatitis, cirrhosis, etc.;\n* Patients with heart failure (NYHA class III or IV), unstable angina pectoris, acute myocardial infarction, severe arrhythmia, and degree II and III cardiac conduction obstruction within 6 months prior to randomization;\n* Those who meet the heavy drinking standard in the three months before the screening period, that is, drinking ≥5 standard drinks per day (1 standard drink is equivalent to 120ml wine, 360ml beer or 45ml liquor);\n* Patients who have abused or become addicted to drugs (narcotics, drugs) in the past year;\n* Patients with malignant tumors or severe systemic diseases with an expected survival of less than 90 days;\n* Patients with serious mental disorders or dementia who cannot cooperate to complete informed consent and follow-up;\n* Participated in any interventional drug or device clinical trials within 3 months prior to screening;\n* Patients deemed unsuitable for study participation by the investigator;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Jinsheng Zeng","role":"CONTACT","phone":"+8613322800657","email":"zengjs@pub.guangzhou.gd.cn"},{"name":"Jian Zhang","role":"CONTACT","phone":"+8613560451639","email":"zhjian55@mail.sysu.edu.cn"}],"overallOfficials":[{"name":"Jinsheng Zeng","affiliation":"First Affiliated Hospital, Sun Yat-Sen University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"The First Affiliated Hospital, Sun Yat-sen University","city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","contacts":[{"name":"Jinsheng Zeng","role":"CONTACT","phone":"+8613322800657","email":"zengjs@pub.guangzhou.gd.cn"},{"name":"Jian Zhang","role":"CONTACT","phone":"+8613560451639","email":"zhjian55@mail.sysu.edu.cn"}],"geoPoint":{"lat":23.11667,"lon":113.25}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000003920","term":"Diabetes Mellitus"},{"id":"D000003924","term":"Diabetes Mellitus, Type 2"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000044882","term":"Glucose Metabolism Disorders"},{"id":"D000008659","term":"Metabolic Diseases"},{"id":"D000004700","term":"Endocrine System Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M6805","name":"Diabetes Mellitus","asFound":"Diabetes Mellitus","relevance":"HIGH"},{"id":"M6809","name":"Diabetes Mellitus, Type 2","asFound":"Type 2 Diabetes","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M11329","name":"Metabolic Diseases","relevance":"LOW"},{"id":"M25093","name":"Glucose Metabolism Disorders","relevance":"LOW"},{"id":"M7552","name":"Endocrine System Diseases","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC19","name":"Gland and Hormone Related Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000007610","term":"Kallikreins"}],"ancestors":[{"id":"D000003029","term":"Coagulants"},{"id":"D000005303","term":"Fertility Agents, Male"},{"id":"D000005299","term":"Fertility Agents"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M10328","name":"Kallikreins","asFound":"eNOS","relevance":"HIGH"},{"id":"M5949","name":"Coagulants","relevance":"LOW"}],"browseBranches":[{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}